We offer a diversified portfolio of products which allows us to capitalize on local and regional customer needs. Generally, our products are promoted to veterinarians and livestock producers by our sales organization which includes sales representatives and technical and veterinary operations specialists, and then sold directly by us or through distributors, retailers and e-commerce outlets. The depth of our product portfolio enables us to address the varying needs of customers in different species and geographies. Many of our top selling product lines are distributed

across both of our operating segments, leveraging our research and development (R&D) operations and manufacturing and supply chain network.

Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to a single product in all brands, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both livestock and companion animals across each of our major product categories.

In the fourth quarter of 2019, the company modified the list of major product categories to include a category for dermatology products, which was previously included within other pharmaceutical products. The prior period presentation has been revised to reflect the new product categories.

•vaccines: biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response;

•animal health diagnostics: portable blood and urine analysis systems and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits and blood glucose monitors.

Our remaining revenue is derived from other non-pharmaceutical product categories, such as nutritionals and agribusiness, as well as products and services in smaller but fast growing areas, including biodevices, genetic tests and precision livestock farming.

Our livestock products primarily help prevent or treat diseases and conditions to enable the cost-effective production of safe, high-quality animal protein. Human population growth and increasing standards of living are important long-term growth drivers for our livestock products in three major ways. First, population growth and increasing standards of living drive increased demand for improved nutrition, particularly animal protein. Second, population growth leads to increased natural resource constraints driving a need for enhanced productivity. Finally, as standards of living improve, there is increased focus on food quality and safety.

Our companion animal products help extend and improve the quality of life for pets; increase convenience and compliance for pet owners; and help veterinarians improve the quality of their care and the efficiency of their businesses. Growth in the companion animal medicines, vaccines and diagnostics sector is driven by economic development, related increases in disposable income and increases in pet ownership and spending on pet care. Companion animals are also living longer, receiving increased medical treatment and benefiting from advances in animal health medicines and vaccines.


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(MILLIONS OF DOLLARS)	2020		2019		2020		2019
United States	$	996	$	844	$	2,605	$	2,342
Australia	60		53		154		150
Brazil	62		72		181		206
Canada	50		47		144		142
Chile	24		22		72		64
China	66		40		198		156
France	29		24		82		83
Germany	38		35		112		111
Italy	28		26		63		82
Japan	39		39		133		118
Mexico	26		29		84		87
Spain	31		29		83		86
United Kingdom	44		46		125		145
Other developed markets	105		98		282		269
Other emerging markets	165		161		490		482
	1,763		1,565		4,808		4,523
Contract manufacturing & human health	23		19		60		63
Total Revenue	$	1,786	$	1,584	$	4,868	$	4,586


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(MILLIONS OF DOLLARS)	2020		2019		2020		2019
U.S.
Companion animal	$	664	$	550	$	1,757	$	1,495
Livestock	332		294		848		847
	996		844		2,605		2,342
International
Companion animal	331		284		917		866
Livestock	436		437		1,286		1,315
	767		721		2,203		2,181
Contract manufacturing & human health	23		19		60		63
Total Revenue	$	1,786	$	1,584	$	4,868	$	4,586


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(MILLIONS OF DOLLARS)	2020		2019		2020		2019
Companion Animal:
Dogs and Cats	$	947	$	789	$	2,524	$	2,231
Horses	48		45		150		130
	995		834		2,674		2,361
Livestock:
Cattle	417		389		1,107		1,148
Swine	151		142		454		449
Poultry	129		135		412		417
Fish	45		42		101		90
Sheep and other	26		23		60		58
	768		731		2,134		2,162
Contract manufacturing & human health	23		19		60		63
Total Revenue	$	1,786	$	1,584	$	4,868	$	4,586


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(MILLIONS OF DOLLARS)	2020		2019		2020		2019
Vaccines	$	401	$	364	$	1,086	$	1,092
Anti-infectives	349		312		870		891
Parasiticides	305		243		867		740
Dermatology	257		222		681		566
Other pharmaceuticals	208		196		597		573
Medicated feed additives	102		112		336		339
Animal health diagnostics	87		69		216		194
Other non-pharmaceuticals	54		47		155		128
	1,763		1,565		4,808		4,523
Contract manufacturing & human health	23		19		60		63
Total Revenue	$	1,786	$	1,584	$	4,868	$	4,586

Contract liabilities reflected within Other current liabilities as of December 31, 2019 and December 31, 2018, and subsequently recognized as revenue during the first nine months of 2020 and 2019 were approximately $6 million and $8 million, respectively. Contract liabilities as of September 30, 2020 and December 31, 2019 were approximately $9 million and $11 million, respectively.